

15 years of

The continuous failure in the prevention and treatment of misinterpretation of an inflammatory autoimmune process

by

Prof. A. Hässig MD

H. Kremer MD

S. Lanka PhD



Summary

The question of the specificity of the anti-HIV antibody test has to be reevaluated as it was shown that the viral enrichment obtained from co-cultivations of patients' lymphocytes with fetal cord blood by Barré-Sinoussi *et al.* and leukemia cells by Gallo *et al.*, exclusively consisted proteins of the cell types used in the cell culture. This precludes a clear separation of presumed retroviral from cellular proteins or extracellular matrix proteins. In this context it was shown that the anti HIV antibody test detects autoimmune antibodies directed against cyto-skeletal proteins e.g. the liver cells. Strongly augmented anti-actin autoantibodies is considered close to pathognomonic for chronically active hepatitis. The original assumption that 'reverse transcription' from RNA to DNA is evidence for the existence of retroviruses, was wrong. In fact, 'reverse transcription' is a vital mechanism for the maintenance of the genome. The decrease in numbers of circulating CD4 lymphocytes can be explained by a stress-induced hyper-cortisolism. Up to date, direct HIV-mediated destruction of CD4 lymphocytes could not be proved. The same is true for measuring of the 'viral load'. Shortcomings of the applied method to quantify the 'viral load' do not permit definitive conclusions. Possibly, it may be taken as an expression of a stress-induced weakening of the cellular immune reactions, in the course of which the nucleoside fragments resulting from the current cell turnover are inadequately eliminated. Furthermore, the treatment of patients with-nucleoside analogues has a toxic effect on both the genome of the cell-nucleus and the mitochondria. The latter, therefore, may produce insufficient amounts of ATP, causing organ failure and, eventually, death. The synthetic protease inhibitors used these days are associated with serious side-effects. Therefore, it seems worthwhile, in these patients, to bring back the catabolic situation due to whole body inflammation to homeostasis by administering anabolic phytopolyphenolic compounds.

AIDS is the abbreviation for acquired immunodeficiency syndrome. AIDS, as a term for an illness, originated in the search by the American Centers of Disease Control for sick homosexual men, also suffering from Kaposi's Sarcoma (KS) and/or Pneumocystis Carinii Pneumonia (PCP). In 1983 Barré-Sinoussi *et al.* reported on a T-lymphotropic retrovirus which they allegedly isolated from an enlarged lymphnode of a homosexual patient.¹ In 1984 Gallo *et al.* reported the alleged isolation of an identical retrovirus from CD4-lymph cells from homosexual patients, clinically diagnosed as suffering from AIDS.² Barré-Sinoussi *et al.* cultivated these patients' lymph cells in question with fetal cord blood and Gallo *et al.* co-cultivated theirs with leukemia cells. Initially, these laboratory methods must raise doubts as to whether the isolation of a new human retrovirus is evident just by data. Gallo *et al.* stated that their allegedly isolated retrovirus caused the destruction of CD4 lymphocytes in those patients, whose heterogenic illness was taken as an after-effect of the CD4-cell destruction and so subsumed as AIDS. Besides, Gallo *et al.* announced that in due time a vaccine would be available for the formation of antibodies against the discovered virus.² Today, fifteen years later, the question still remains open, whether HIV retroviruses actually do exist or whether the postulated retroviral 'HIV'-antigens as well as the postulated 'HIV' reverse transcription are a matter of human protein molecules derived from cells in co-cultured cell cultures used by both Barré-Sinoussi *et al.* and Gallo *et al.* The most extensive investigations in this regard are owed to Eleni Papadopulos-Eleopulos and her group in Perth, Australia. In 1993 they published a review concluding that there is no evidence for the existence of HIV viruses.³ In 1994 Lanka concluded that all 'retroviruses', including 'HIV', are biologically nonexistent and their phenomenology is based on laboratory artefacts.⁴⁻⁶

These fundamental counter-statements to the current HIV-AIDS-theory have been strongly supported in the last few

AIDS

AIDS is rooted in the
as a lethal, viral venereal disease

Prof. W-X Liang MD



K. Stampfli MD



years. Upon investigations in order to develop a vaccine against 'HIV' it became apparent, that the enrichment of presumed HIV-1 preparations, considered as pure, consist of proteins of the cell types used in the cell cultures, which resist a clean separation into presumed retroviral and cellular proteins, i.e. extracellular matrix proteins. Above all, these cell proteins, also occur in the inside of extracellular particles, which have been misread as it seems as so-called III virions by the retrovirologists.⁹⁻¹⁰ These findings were to be expected as Gallo *et al.*, when developing the 'AIDS test', did not investigate the presence of cells' own proteins in the protein mixture, released during the co-cultivation of patients' lymphocytes and leukemia cells. Upon developing the ELISA and Western Blot tests it should have been imperative to consider proteins released from stimulated leukemia cells, not being mixed with patients' lymphocytes, and to differentiate these from the ones, released only after addition of patients' lymphocytes.

In view of this it seems to be mandatory to re-evaluate the question of the specificity of the anti-HIV antibody test.

What is the laboratory finding "anti-HIV-positive" based on?

In a series of preceding reports we have discussed this question in detail¹¹⁻¹⁴. We came to the conclusion: the laboratory finding "anti-HIV- positive" is primarily the expression of an autoimmune activation of the immune system linked to a persistent catabolic state of metabolism. In view of the fact that the diseases grouped under the term AIDS are limited to risk groups such as homosexuals, drug addicts and recipients of blood products contaminated with parenterally transmitted hepatitis inductors, the question is raised, whether the anti-HIV test determines autoantibodies

directed against cell envelope structures with a specificity to the body's own proteins of the host cells. It has been known for over twenty years that chronically active hepatitis (currently hepatitis B, hepatitis C and autoimmune hepatitis without evident antiviral antibodies) react by the formation of autoimmune antibodies directed against cyto-skeletal proteins of the liver cells. Thus, the raised anti-actin-autoantibodies are pathognomonic for chronically active hepatitis¹⁵. Johnson *et al.*, in 1965, were the first to report on anti-actin-autoantibodies¹⁶. They described autoantibodies directed against smooth muscle cells and showed that this had to be considered as characteristic indication of "lupoid hepatitis". In 1973 Gabbiani *et al.* demonstrated that autoantibodies directed against smooth muscle cells react with actin-containing microfilaments¹⁷. Further investigations indicate that autoantibodies with anti-actin specificity are to be classified within the big group of autoantibodies against filamentous proteins of smooth muscle fibres. 3 - 18% of healthy individuals present low titer autoantibodies against cyto skeletal proteins¹⁸. High titer anti-actin autoantibodies, on the other hand, are only found in patients suffering from chronically active hepatitis and/or biliary cirrhosis.¹⁹ In 1994 Bermas *et al.* showed that both sera from patients with lupus erythematosus and from mice suffering from the same illness react with glycoprotein 120 and peptides of the postulated HIV-1 envelope.²⁰ They further proved that control sera of healthy individuals and patients with other autoimmune diseases contain small amounts of the same autoantibodies. Last but not least, they showed that autoantibodies reacting with glycoprotein 120 do not possess antinuclear specificity. They refrained from investigating a specificity against cytoskeletal proteins of these autoantibodies.

Evidence is given that the HIV test does not indicate antibody formation against the postulated retroviruses as,

during the last decade in Germany, not a single seroconversion has been observed in imprisoned drug addicts. All seropositive drug addicts acquired their anti HIV 'positivity' before their imprisonment. In opposition to this, seroconversion by hepatitis B inductors was recorded in intravenous drug addicts²¹⁻²³. The same was also observed in haemophiliacs, i.e. despite continuous substitution with heparin-contaminated blood products approximately a third of these individuals never become anti-HIV positive. This is characteristic for the individual response to autoimmune reactions against cyto-skeletal proteins in the host cells, in which Girard and Senecal observed a polyreactivity²⁴. The individual autoimmune reactivity either appears at first contact or fails to appear even at multiple contacts.

We conclude that a positive anti-HIV test does not indicate an antibody formation against "retroviral HIV antigens". Low titer "anti HIV" antibodies are common even in healthy individuals. High titer antibodies are pathognomonic in chronically active hepatitis. The anti HIV test does not answer the question whether anti HIV antibodies occur or not; the test differentiates between "plenty = positive" and "few = negative".

Rethinking as to "Reverse Transcription"

The error, taking proteins resulting from 'HIV' isolation for retroviral proteins, dates back to 1970. The paradigm, that DNA codes information and programs relating to all physiological and phenomenological aspects of all organisms, resulted in the postulation of the irreversibility of the genetic flow of information for the synthesis of proteins - from DNA via messenger substance (RNA) to proteins. This was the crucial genetic dogma²⁵. Despite the proven reversibility in 1970, that from RNA DNA can re-emerge, this fact was postulated as an exception that proves the rule by stating the existence of retroviruses, qualified for this reversibility, which, at this time, were only considered as tumor viruses.^{26,27} With the discovery of this enzymatic activity in all living cells it soon became clear that the evidence of the function of "reverse transcription" from DNA into RNA was not a proof for the existence of retroviruses, because the genome of all eukaryotic cells is clearly marked by this activity^{28,29}. Retrospectively, it seems rather astonishing that in 1983 Montagnier and in 1984 Gallo still postulated a new retrovirus despite the fact that a new viral entity had never been isolated or described, according to the standard regulations in virology. As a matter of fact, the enzyme Reverse Transcriptase from 'HIV' has never been isolated or described, but only inferred from functions to its existence, when new formation from DNA into RNA was proven by laboratory techniques.

Since 1985 it has been known that the 'Reverse Transcription' plays a decisive role in the maintenance of the structure of the genome, by repairing chromosome fractures and, especially, by limiting the loss of chromosomal end components, the telomeres occurring at cell replication^{30,33}. The respective enzymes for this kind of reverse transcription, the telomerases dispose of a type-specific RNA matrix for the formation of the repeating telomer units. Somatic human cells, that do not belong to the reproductive path, cannot adapt to the shrinking of their telomeres when replicating and so cease the replication at a certain degree of depletion.

Up to date, the influence of nucleoside analogues on the action of telomeres at replication has obviously not been investigated: We could trace only two publications, in 1996, which describe an *in vitro* investigation of nucleoside analogues inhibiting the telomerase activity. In our view, the knowledge, already gained in 1980, on the vital physiological function of 'reverse transcription' should have lead to a

relinking as to the establishing of nucleoside analogues as pharmacological inhibitors that time on the physiological function of the 'Reverse Transcription', it should have been rejected.³⁴⁻³⁵

What is the decrease of CD4-lymphocytes in AIDS based on?

The decrease of the circulating CD4-lymphocytes in the blood stream during progressive immune deficiency in AIDS has generally been explained by the progressive destruction caused by HI viruses³⁶. Four years ago Carbonari *et al.* showed in an *in vitro* investigation that the apoptosis of the lymphocytes in AIDS patients is mainly related to CD8 - T-cells and CD19 B-cells³⁷. Finkel *et al.* then pointed out that apoptosis concerns mainly 'bystander' cells and spares supposedly infected cells from so-called HIV- and SIV lymphnodes³⁸. These reports remind us of Fauci's classical publications of the 70's in which he and his working group clearly demonstrated that, in persisting hypercortisolism, an increasing number of CD4-cells leave the blood stream and can thus activate B-cells in the marrow.^{39,44} The migrated CD4-cells return to the blood stream upon dropping to normal values of the cortisol level.

At the beginning of 1995 Wei and Ho *et al.* published a report in which they declared, that the extremely fast multiplication of HI-1 viruses produces a raised turnover of CD4-lymphocytes.^{45,46} Towards the end of 1996 Wolthers *et al.* showed that the telomere length of CD4-lymphocytes in anti-HIV positive individuals remains normal, whereas the one of CD8-cells decreases.⁴⁷

During the latest international congress of leading HIV scientists the long term criticism of the HIV/AIDS theory has been confirmed: despite intense and precise investigations there was no proof of a pathophysiological mechanism explaining the different reaction of CD4- and CD8-lymphocytes to the postulated retrovirus HIV.⁴⁸ It was literally stated: "The riddle of CD4 cell loss remains unresolved." Paul Johnson of the Harvard Medical School in Boston voiced in a disillusioned way the helplessness of the conventional AIDS scientists: "We are still very confused about the mechanism that leads to CD4 depletion, but at least now we are confused at a higher level of understanding. In other words, Fauci's pioneering work, based in the seventies, on experimental traumatology fell into oblivion. Calvano clearly documented in a review published in 1986 that the selective depletion of CD4-lymphocytes is induced by neuroendocrine mechanisms in traumatic conditions such as injuries and burns, whereas its proportions depend on the degree of hypercortisolism⁴⁹. It remains enigmatic why Fauci, after having joined the AIDS research, never again mentioned his own reports:

What does the "viral load" measure?

Immediately, after the publication of Wei's and Ho's reports in January 1995^{45,46} in which they put forward the hypothesis that HI viruses multiply at raving speed destroying a similar number of CD4 helper cells, quantitative tests based on the genetic multiplication method PCR were introduced and so a large number of 'HIV' in the blood stream was postulated. It has been well known among 'HIV' scientists that the so-called viral load, i.e. the measurement of the 'viral load' - "is no evidence of the entire virus genome or intact viruses"⁵⁰. The "viral load" measures short components of the messenger substance RNA, attributed to the HI viruses. Because the virus genome *per se* never could be described it is impossible to designate these RNA fragments as viral. Going through the records of the presumed characterization of 'HIV' it can be inferred that all components -

proteins and genetic substance - attributed to HIV, are of pure cellular origin.⁵³ Therefore, the results of the 'viral load' can only have an indirect significance, such as the measurement of an increase or decrease of cellular RNA, as it can be observed as increasing in catabolic conditions of cell disintegration and decreasing in anabolic conditions. However, these results cannot be considered as clinically relevant as, besides the technical inadequacy, control investigations with both non-positive defined healthy and ill individuals have never been published.

The polymerase chain reaction (PCR) is a technique for a manifold multiplication of short DNA fragments, developed by Nobel prize winner for chemistry, Kary Mullis. Upon measuring the 'viral load' the RNA fragments in the blood stream first have to be converted into DNA and then multiplied as such. The single, developing technical steps of this method are prone to failure. The slightest impurity, drugs, such as heparin and other substances interfere with a reproducible functioning of the PCR method, especially with quantification.⁵³ Kary Mullis, the inventor of this method does not miss any occasion to criticize the application of his technology in the context of AIDS.⁵⁷ Furthermore, it is concealed that it does not make sense, either practically or theoretically, to initially multiply manifold fragments of genetic structure and then to postulate their manifold presence. In case they were actually present in the blood samples it would cause no problem to prove their existence by simple, quick and cheap standard methods⁵¹ and, if de facto, viruses did exist in the blood stream, scientists certainly would have been successful in making them visible. Hence, up to date, no scientist claims this achievement, a fact which has been confirmed under coercive evidence by the German Health Ministry in 1996. After the report of a produced "positivity" in the "viral load" during a vaccination test with proteins⁵⁴ of a previously "negative" defined test person it is now frankly admitted that repeated wrong-positive results in the viral load are quite a well known phenomenon.⁵⁵

Impairment of energy formation in mitochondria by nucleoside analogues such as AZT (Azidothymidine, Zidovudine)

AIDS patients quite often demonstrate a weakening of their skeletal muscles. Up to 1990 this was considered a HI-virus-caused impairment of muscles. In 1990 Dalakas *et al.* demonstrated that this kind of muscle disease is due to an administration of AZT, weakening the mitochondria within muscle cells. With the excessive release of free radicals the mitochondria are affected in their function of forming ATP as key substance in metabolic energy.⁵⁶ Hayakawa *et al.*, in 1991, demonstrated important changes in the mitochondrial DNA (mtDNA) in the liver of mice after the administration of AZT. The final sentence of this paper reads: "However, for AIDS patients it is urgently necessary to develop a remedy substituting this toxic substance AZT".⁵⁷ These results were confirmed by histochemical methods in the same year by Chariot and Gherardi.⁵⁸

The toxicity of nucleoside analogues in the treatment of viral diseases was thoroughly dealt with in the following years and, it was proven that the toxic effect causes multi-organic impairments in heart muscle, brain and kidney, as well as in liver and pancreas.⁵⁹ Further, it was shown that successor drugs of AZT such as ddI and ddC cause the same mitochondrial impairment.⁶⁰ Since 1991 it would have been mandatory that not only the pharmaceutical industry but also the registration authorities seriously consider these impairments caused by long-term administration of nucleoside analogues and provide proof of the incoherence of AIDS patients' death with this drug treatment, in general

this obligation has been avoided and now they face upcoming connected liability questions.

HIV-proteases inhibitors: A new therapeutic principle in the prevention and treatment of AIDS

According to the HIV-model long precursor molecules of proteins along the multiplication process, have to be cut at certain interfaces in order to create functional 'HIV' proteins upon which, ultimately, new HI viruses form. Synthetically produced short protein molecules, reproduced after the interface to be cut from the precursor protein but which cannot be cut, should, according to the model again, inhibit the natural activity of the HIV protease and thus prevent the formation of new HI viruses. As a matter of fact the 'HIV' protease has not been isolated, but has been reconstructed by genetic engineering upon which it was observed that this enzyme is very similar to the human digestive enzyme, pepsin of the class of the aspartate proteases. The problem of the model is that the one and the very same 'HIV' protease would have to be cut at completely different interfaces in order to form functional proteins and, ultimately, 'HIV'. Practically, this is not conceivable and has been explained as: "enzymes do not have a high sequence specificity" although it has been postulated that: "a therapeutically applicable inhibitor has to be specific, and should not inhibit human enzymes of this class of substance."⁶¹ Considering these explanations of the head of the chemical department of the scientific laboratories at Bayer's, it becomes obvious that, theoretically, it is not possible to exactly target the postulated HIV protease. Further, it is impossible not to interfere in the cellular processes of integration and disintegration of a variety of proteins. The inhibition of the active protease in AIDS *per se* makes sense. However the pharmacological administration of high doses of distinct aromatic substances is a non-physiological measure, connected with serious side-effects which excludes their pharmacological use. Indeed, up to date, the pharmacological 'HIV' protease inhibitors prove to be connected with side-effects, which demand the absolute necessity of their replacements by phyto-therapeutic mixtures. Apart from side-effects such as kidney stones, damage of the liver, an increase of diabetic impairment of metabolism, CMV retinitis and haemolytic anaemias these protease inhibitors, after a short-term administration, also demonstrate a loss of effect on the inflammatory process which was misinterpreted as a result of an acquired resistance by HIV as well as an incompatibility with many drugs, especially with the ones of the group of Cytochrom-P450-inhibitors and inductors.⁶²

Nutritional possibilities in the prevention and treatment of AIDS

Looking at the formula of structure of the synthetic protease inhibitors, it becomes obvious that these are artificially produced aromatic compounds. As we have suggested lately, polyphenols as well as tannins and flavonoids are phyto-protective substances against harmful external influences. As aromatic substances, they cannot be synthesized by the animal organism. The nutritional supply of a variety of phyto-polyphenols to the animal organism has the function of operating as a redox buffer and rebalancing oxidative stress conditions with their catabolic alteration of metabolism to the anabolic state of equilibrium.⁶³

Flavonoids and tannins are effective with respect to:

1. Inhibition of lipid peroxidation
2. Scavenging of oxygen radicals
3. Binding and inactivation of pro-oxidative transition metals such as Fe and Cu
4. Binding of proteins including attenuation of their enzymatic activity (protease inhibitors)

Upon these reductive activities flavonoids and tannins are oxidized themselves, a well known example is the reduction of vitamin E by vitamin C or coenzyme Q. These mechanisms are at the beginning of a cascade of recycling. This example demonstrates, that the multitude of almost 5000 different flavonoids and tannins is used to overcome the oxidative state of the ex-antioxidative molecules at the end of the cascade of recycling, by transferring it to a variety of native molecules.

The stress-induced state of catabolic metabolism in AIDS is in the center of the pathogenesis. The correction of the connected whole body inflammations, caused by oxygen radicals and protease activation, is a compelling preventive and therapeutic action which urgently demands the use of phyto-therapeutic polyphenol compounds.

Possibilities and limits of treatment of hepatitis in anti-HIV positive individuals

A symptomlessness and the stress-induced activation of liver inflammation in healthy individuals are characteristic of parenterally transmitted inoculation hepatitis (hepatitis B and C). The classic example for this occurrence is posttransfusional hepatitis caused by blood and blood products of clinically healthy blood donors. At the occasion of a study, made in the early fifties at the blood transfusion service of the Swiss Red Cross on recipients of lyophilized pools of mixed plasma of 50 - 70 healthy blood donors, it was observed that this caused serious, sometime even lethal hepatitis in many ill recipients.⁶⁴⁻⁶⁶ It is emphasized that in a contaminated organism with parenterally transmitted hepatitis inductors (now called hepatitis B and C), the aim of treatment has to be reduced to just reach a normal state of health. The administration of virucide, cytotoxic drugs is not able to eliminate these inductors from the organism. Proceeding from this knowledge, in Poland, for two decades, BRZOSKO *et al.* have been collecting data with the Tibetan prescription of phyto-therapeutic formula, PADMA 28⁶⁷. They showed that this phenol-rich plant compound is able not only to reduce the serum level of hepatitis B antigens in hepatitis B patients but also to augment the serum level of hepatitis B antibodies. At the same time an amelioration was observed in these patients regarding their clinical condition and the biochemical and histological results from their hepatitis. Based on these pioneer results, today, in patients suffering from chronically active hepatitis, the substitution with phyto-polyphenolic mixtures has priority over other treatments.

How does the nucleoside analogues treatment of AIDS patients influence their course of disease?

After having examined 8 reports on 'HIV' positive long-term non-progressors who stayed clinically symptomless for over 10 years, we realized, that, without exception, they had not been treated with nucleoside analogues.⁶⁸⁻⁷⁵ We consider this as a confirmation of our above-mentioned caution as to the prophylactic and therapeutic administration of these cell toxic, originally developed for treating cancer,

in the autoimmune course of disease in AIDS.

Nutritional supply of polyphenolic mixtures as basic treatment of anti-HIV positive individuals and AIDS-patients

As initially showed, a positive anti-HIV test is an indication of an augmented formation of autoantibodies against cytoskeletal proteins, i.e. actin. This condition is pathognomonic for chronically active hepatitis. AIDS, as serious immuno-deficiency-syndrome is the expression of a persistent hypercatabolic state of metabolism along with a stress-induced whole body inflammation. A successful treatment of such conditions consists of the nutritional supply of a sufficient quantity of antioxidative and antiproteolytic phyto-phenolic mixtures, consisting of flavonoids and tannins. As neither the animal nor the human body are able to synthesize aromatic compounds they are fully dependent on a sufficient supply of anabolic effective phyto-polyphenolic mixtures, in order to adjust catabolic states of metabolism. These mixtures are present in drugs made of teas and spices. Padma 28 proved to be the most effective one. Additionally, it is recommended to balance other possible states of deficiency of vital nutritional components such as polyanions and essential fatty acids. Completing this review we came across the publication by PADIAN *et al.* which remarkably emphasizes the insignificance of heterosexuals transmitting 'HIV'. In this study, extended to 10 years, the authors say: "male-to-female transmission was approximately eight times more efficient, than female to male transmission and male-to-female per contact infectivity was estimated to be 0.0009". Obviously, AIDS is not a viral venereal disease, but an inflammatory autoimmune process⁷⁶.

References:

1. Baris-Simonsi F, Cherman JC, Rec F *et al.* Isolation of a T-tropotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 1983;220:868-871
2. Gallo RC, Salahuddin SZ, Poprovic M *et al.* Frequent detection and isolation of cytopathic retroviruses (HIV-1) from patients with AIDS and at risk from AIDS. *Science* 1983; 221:1503-1504
3. Papadopoulos-Eleopoulos E, Turner VF, Papadimitriou JM. Is a positive western blot proof of HIV infection? *Dermatology* NY 1993; 169:707.
4. Linka S. Fehldiagnose AIDS. *Wissenschaften*, Aachen, December 1994; 48:53.
5. Linka S. HIV - Realität oder Anekdote? *Rassid und Zeit* 1995; 77:17-27
6. Linka S. HIV - reality or anecdote? *Guertner* 1995; 37:4-9.
7. Papadopoulos-Eleopoulos E. (Interview): Is HIV the cause of AIDS? *Guertner* 1997; 3:8-19.
8. Gianchiarini P, Moirio I, Goldeloni HR, Sattenica QJ. Cell membrane vesicles are a major component of gradient-enriched human immunodeficiency virus type 1 preparations. *Virology* 1997; 230: 125-133
9. Bova JW, Gurebekk RJ, Kuebe WJ, Henderson LE, Arthur LO. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. *Virology* 1997; 230:134-144.
10. Ott DE, Cohen LV, Kaine BP *et al.* Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. *Journal of Virology* 1996; 70: 7734-7741
11. Hsing A, Kremer H, Liang WX, Stampf K. Offene Fragen zur Spezifität der Anti-HIV-Antikörper. *Schweiz Ztschr GesundheitsMed* 1996; 4(6): 294-298.
12. Hsing A, Kremer H, Liang WX, Stampf K. Parenteral übertragene Hepatitis-Viren und AIDS. *Schweiz Ztschr GesundheitsMed* 1996;4(7/8): 325-330.
13. Hsing A, Kremer H, Liang WX, Stampf K. Hypercatabole Krankheiten. *Schweiz Ztschr GesundheitsMed* 1997;9(7):70-85
14. Hsing A, Kremer H, Linka S, Liang WX, Stampf K. AIDS und Autoimmunität. *Schweiz Ztschr GesundheitsMed* 1997;9(5): 219-222.
15. Gezege J, Shoenfeld Y. Actin autoantibodies. In: *Autoantibodies* (Eds: JP Peter, Y Shoenfeld). Amsterdam: Elsevier, 1996: 70-12.
16. Johnson GD, Halbarrow EJ, Glavin LE. Antibody to smooth muscle in patients with liver disease. *The Lancet* 1965; II:876-879.
17. Galisiani G, Ryan GD, Laveille JP *et al.* Human smooth muscle auto-antibody, its identification as actin-actin antibody and a study of its binding to "non-muscular" cells. *American Journal of Hematology* 1975; 72:473-488.
18. Figuera A, Norberg R. Anti-actin antibodies. *Curr Top Microbiol Immunol* 1978; 82:1-13.
19. Henlen AN, Berg PA. Haemagglutinating anti-actin antibodies in acute and chronic liver disease. *Gut* 1980; 21:311-317.
20. Berana BL, Petit M, Barozsky JA, Wainman A, Shesser GM, Moses E. Binding of glycoprotein 120 and peptides from HIV-1 envelope by anti-actin antibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. *AIDS Res Hum Retroviruses* 1994;10:1071-1077.
21. Weiland C, Rotty M. European network on HIV/AIDS prevention in prisons. Final Report. Bonn, 1997.
22. Sörer H, Weiland C. Prävalenz viraler Infektionskrankheiten und Infektionslevenszyklen. Rückversicherung im deutschen Justizvollzug. *Infektionsmedizin* 1997; 6(6):22-27.

23. Meyenberg B, Söder H, Jacob J *et al*. Infektionsprophylaxe im neonatalen Säuglings-Justizvolk. Bibliotheks- und Dokumentensystem der Universität Oldenburg. Oldenburg, 1996.

24. Grand D, Senter JL. Anti-microfilament IgP antibodies in a panel of adults and in patients with autoimmune disease: Immunofluorescence and immunoblotting analysis of 291 subjects reveals polyreactivity with microfilament-associated proteins. *Glia Immunol Immunopathol* 1995; 74:193-204

25. Strahman RC. The turning Kellman revolution in biology. *Nat Biotechnol* 1995; 13:194-200

26. Tamis HM, Mizutani S. RNA-dependent DNA polymerase activities of *Borna ostreae* virus. *Nucleic Acids Res* 1970; 226:1211-1213,25.

27. Temin HM, Baltimore D. RNA-directed DNA synthesis and RNA virus variants. *Adv Virus Res* 1972; 7:129-186.

28. Temin HM. Reverse transcription in the eukaryotic genome: Herpesviruses, paramyxoviruses, retroviruses, and retrotransposons. *Mol Biol Evol* 1985; 2:455-469

29. Baltimore D. Retroviruses and retrotransposons: The role of reverse transcription in shaping the eukaryotic genome. *Curr Opin* 1985; 4:461-467.

30. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. *Semin Oncol* 1996; 27:42-80

31. Boeke JD. DNA repair: A little help for my criz. *Nature* 1996; 383:570-581.

32. Teng SC, Kim B, Goshrie A. Retrotransposon reverse-transcriptase-mediated repair of chromosomal breaks. *Nature* 1996; 383:641-644.

33. Teng SC, Kim B, Lindahl A. DNA repair by rejoining reverse transcripts. *Nature* 1997; 386:31-37.

34. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. *Mol Cell Biol* 1996; 16:55-63

35. Yegorov YE, Chernov DN, Akimov SS, Bolshova NL, Kazayevsky AA, Zakharen AV. Reverse transcriptase inhibition suppresses telomerase function and induces senescence like processes in cultured mouse fibroblasts. *FEBS Lett* 1996; 399:115-118

36. Hässig A, Liang WX, Stampfli K. Reappraisal of the depletion of circulating CD4+ lymphocytes in HIV-1 carriers in transition to AIDS. *Crossroads* 1995; 3:16-20

37. Carbonari M, Gilani M, Lynch M *et al*. Detection and characterization of atypical peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometry method. *Blood* 1994; 83:1-266-177

38. Enkel TL, Tucker-Winters G, Bandt NK *et al*. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and HIV-1-infected lymph nodes. *Nature Medicine* 1995; 1:129-136.

39. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. *J Clin Invest* 1974; 53:740-746.

40. Fauci AS, Dale DC. The effect of hydrocortisone on the kinetics of normal human lymphocytes. *Blood* 1976; 46:235-243.

41. Fauci AS, Pratt KR. Activation of human B lymphocytes. I. Direct plaque-forming cell assay for the measurement of polyclonal activation and antigenic stimulation of human B lymphocytes. *J Exp Med* 1976; 144:674-684.

42. Fauci AS, Pratt KR, Whalen G. Activation of human B lymphocytes. II. Cellular interactions in the PFC response of human tonsillar and peripheral blood B lymphocytes to polyclonal activation by pokeweed antigen. *J Immunol* 1976; 117:2100-2104.

43. Haynes BF, Fauci AS. Activation of human B lymphocytes. III. Concanavalin A-mediated generation of suppressor cells of the plaque-forming cell response of normal human lymphocytes. *J Immunol* 1977; 118:2281-2287.

44. Fauci AS, Pratt KR, Whalen G. Activation of human B lymphocytes. IV. Regulatory effects of concanavalin on the antigenic signal in the plaque-forming cell response of normal human B lymphocytes. *J Immunol* 1977; 118:548-553.

45. Wei X, Gao S, Taylor ME *et al*. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature* 1995; 373:117-122.

46. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* 1995; 373:123-126.

47. Waldherr RC, Winters GB, Oles SA *et al*. T cell telomere length in HIV-1 infection: No evidence for increased CD4+ T cell turnover. *Sience* 1996; 274:1543-1547.

48. Baler M. How does HIV overcome the body's T-cell body guard? 11th Colloquium of the Centre for AIDS, Cannes - Cote d'Azur, France, 27 to 29 October, 1997. *Sience* 1997; 278:1399-1400

49. Calvano SE. Hormonal mediation of immune dysfunction following thermal and traumatic injury. In: *Advances in host defense mechanisms* (Eds. J. Galis, AS Fauci). Vol 2. New York: Raven, 1986; 111-142.

50. Wittfälliger U. Die Methode der PCR im Routinelabor. Hismo (Bern), 1997 (Jan) 2-4.

51. Marcus F, Brusch EF, Sambrook J. *Molecular cloning: A laboratory manual*. New York: Cold Spring Harbor, 1982.

52. Nall G. AIDS - a second opinion. New York/London, 1997. (video available at Constitution, 173 Foundling Court, Brunswick Centre, London WC1N 1 QL, UK.)

53. Hagen-Maria K, Mann W, Quamranie PCR. In: PCR im medizinischen und biologischen Labor. Hrsg. M. Wink, H. Weide. GFT, 1994.

54. Schwarz DJE, Lacyendeker OB, Arango-Jaramillo S, Castaño RC, Reynolds MJ. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. *The Lancet* 1997; 350:256-259.

55. Wilber J. Disconnecting between routine HIV vaccine and response to HIV. *The Lancet* 1997; 350:336-334.

56. Dalakas MC, Ili L, Pzeslajgor GH, Laskaris JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. *New England J Med* 1990; 322:1098-1105.

57. Hayakawa M, Ogawa T, Sugiyama S, Tanaka M, Onawa T. Massive conversion of plasmid to 8-hydroxy-guanidines in mouse liver mitochondrial DNA by administration of zidovudine. *Biochem Biophys Res Commun* 1991; 176:97-99.

58. Charot P, Gherard R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. *Neurological Disorders* 1991; 1:347-350.

59. Laven W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. *Nature Medicine* 1995; 1:417-422.

60. Benbrook E, Charot P, Bonaventura S *et al*. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC) on cultured human muscle cells. *J Neurol Sci* 1997; 149:19-25.

61. Hässig A. HIV-infektion und AIDS. Biologische Grundlagen und chemio-therapeutische Ansätze. *Cheminica Acta* 1991; 76:295-307.

62. Christian. Deutsche Ärztezeitung vom 21.11.97. Text der Packungsbeilage.

63. Hässig A, Liang WX, Schwald H, Stampfli K. Favoviridae und Tumor. Parasitische Antikörper mit Nucleocapsidkern. Ueber die Bedeutung der rezenten Zellen eines maritimen Genos von Favoviren und Tumor. *Schweiz Zeitschrift GesundheitsMed* 1997; 94(4): 171-175.

64. Hässig A, Rüe B von, Vetterli R. Zur Frage der Hepatitisübertragung durch Blut- und Plasmatransfusionen. *Schweiz Med Woch* 1993; 83:483-492.

65. Dubé P, Feldmann H, Hässig A, Heim U, Portmann U, Schreiner W, Zentgraf P. Zur Frage der Hepatitisübertragung durch ultraviolett bestrahltes lyophilisiertes Mischplasma. *Schweiz Med Woch* 1994; 84:1187-1192.

66. Hässig A, Heim R, Stampfli K. Zur Prophylaxe von Hepatitisübertragungen bei Plasmatransfusionen. *Schweiz Med Woch* 1988; 85(6):614-615.

67. Brzoska WJ, Janaszewicz A, PADMA 28 bei chronischer Hepatitis B: Klinische und immunologische Wirkungen. *Schweiz Zeitschrift GesundheitsMed* 1992; 4(Suppl.):13-14.

68. Buchbinder SP, Katz MH, Hessel NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. *AIDS* 1993; 7:1523-1528.

69. Houser DR, Ramirez CH, He Y, Phair J, Graham NMH. Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10⁶/L. *AIDS* 1995; 9:145-152.

70. Hegerlars E, Jarratts S, Wolff J *et al*. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24 antigen but not V3-specific antibody levels. *J Infect Dis* 1995; 171:811-821.

71. Cao Y, Qiu L, Zhang L, Sakai J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. *New England J Med* 1995; 332:201-208.

72. Parillo G, Menzies S, Vaccarezza M *et al*. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. *New England J Med* 1995; 332:309-316.

73. Haerzi T, Haerzi L, Kalish SA *et al*. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. *AIDS Res Hum Retroviruses* 1996; 12:585-592.

74. Marchant DC, Parillo G, Fink LM *et al*. Neutralizing and infection enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. *J Infect Dis* 1996; 173:60-67.

75. Garghula AK, Saly R, Di Caro A *et al*. In vitro activation of HIV RNA expression in peripheral blood lymphocytes as a marker to predict the stability of non progressive status in long-term survivors. *AIDS* 1996; 10:17-21.

76. Padua NS, Shibeck SC, Ghan SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in Northern California: Results from a ten year study. *American J Epidemiol* 1997; 146:330-337.

Addresses of the authors:
Prof. A. Hässig, Prof. Liang Wen-Xi, Dr. K. Stampfli, Study Group on Nutrition and Immunity, Elisabethenstr. 51, CH-3014, Bern, Switzerland.

Dr. H. Kremer, Metzendorfer Weg 36, D-21224 Rosengarten-Tötensen b., Hamburg, Germany.
Dr S. Lanka, Im Dreieck 8, D-44143 Dortmund, Germany

MEDICINA HOLISTICA
 Medicinas Complementarias nº 49-50



FRASES DE OTRA FORMA
 Analisis Desatoxicación de drogas
 Delirios atípicos
 Cáncer
 Efectos de la radiación
 Infecciones bacterianas
 Abstracciones alérgicas
 Dolor faringeo

DEBATE DE LA SEMANA

INVESTIGACION ACTUAL
 Procesamiento endocrinológico
 Psicología, Ontogenética

DOSSIER LA MEDICINA EN VIETNAM

INDICE 2006

Solicita información gratuita:
AMC Prado de Torrejón 27, Pozuelo de Alarcón 28224 Madrid
Tel: (+34) 91 351 21 11 (16,00-20,00horas) Fax (+34) 91 351 21 71
e-mail: amcmh@amcmh.org - http://www.amcmh.org